Astragaloside II
(Synonyms: 黄芪皂苷 II; Astrasieversianin VIII) 目录号 : GN10795
Astragaloside II 是从黄芪中分离出来的天然产物。
Cas No.:84676-89-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Astragaloside II (AST II) is a monomer of Astragalussaponin.
In vitro: Astragaloside II increased the CD45-mediated of pNPP/OMFP hydrolysis in a concentration-dependent manner. The EC50value was 9.23μg/mL.10 and 30 nmol/L astragaloside II treatment significantly enhanced the proliferation of primary splenocytes induced by ConA, alloantigen or anti-CD3. 30 nmol/L astragaloside II treatment significantly increased IL-2 and IFN-γsecretion and upregulated the mRNA levels of IFN-γand T-bet in primary splenocytes. Inprimary CD4+T cells,astragaloside IIpromoted CD25 and CD69 expression upon TCR stimulation. Furthermore, treatment with 100 nmol/L astragaloside II promoted CD45-mediated dephosphorylation of LCK (Tyr505) in primary T cells [1]. Astragaloside IIshowed a significant induction of cell proliferation, differentiation and mineralization in theprimaryosteoblasts [2]. In 5-fluorouracil-resistant human hepatic cancer cells Bel-7402/FU, 0.08mg/ml Astragaloside II increased the cytotoxicity of 5-fluorouracil [3].
In vivo: In CTX-inducedimmune-compromised mice, oral administration of astragaloside II (50 mg/kg) promoted the proliferation of splenic T cells while showed no effects on the proliferation. Astragaloside II also promoted the production of IFN-γand IL-2 [1].
References:
[1].Wan C, Gao L, Hou L, et al. Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity[J]. [2].ActaPharmacologicaSinica, 2013, 34(4): 522-530.
[3].Kong X H, Niu Y B, Song X M, et al. Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways[J]. International journal of molecular medicine, 2012, 29(6): 1090-1098.
[4].Huang C, Xu D, Xia Q, et al. Reversal of P‐glycoprotein‐mediated multidrug resistance of human hepatic cancer cells by AstragalosideII[J]. Journal of Pharmacy and Pharmacology, 2012, 64(12): 1741-1750.
| Cas No. | 84676-89-1 | SDF | |
| 别名 | 黄芪皂苷 II; Astrasieversianin VIII | ||
| 化学名 | Astrasieversianin VIII | ||
| 分子式 | C43H70O15 | 分子量 | 827.02 |
| 溶解度 | DMSO : 150 mg/mL (181.38 mM; Need ultrasonic) | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2092 mL | 6.0458 mL | 12.0916 mL |
| 5 mM | 0.2418 mL | 1.2092 mL | 2.4183 mL |
| 10 mM | 0.1209 mL | 0.6046 mL | 1.2092 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。